RSS-Feed abonnieren
DOI: 10.1055/s-0037-1614982
Monocyte Procoagulant Activity Induced by Adherence to an Artificial Surface Is Reduced by End-point Immobilized Heparin-coating of the Surface
Publikationsverlauf
Received
02. Juni 1997
Accepted after revision
23. September 1997
Publikationsdatum:
08. Dezember 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199802/lookinside/thumbnails/10-1055-s-0037-1614982-1.jpg)
Summary
Heparin-coating improves the biocompatibility of blood contacting artificial surfaces. This led us to investigate the impact of heparin-coating (Carmeda AB, Stockholm) of polymetylmetacrylate on the expression of monocyte tissue factor procoagulant activity (TF-PCA) by surface adhesion. Also, the anticoagulant effect of heparin-coating in the presence or absence of adherent procoagulant monocytes was assessed. This is of particular interest, since activation of extrinsic coagulation by adherent monocyte TF-PCA may play a significant role in thrombin generation during extracorporeal circulation.
Monocytes exposed to heparin-coated or non-coated polymetylmetacrylate expressed TF-PCA. The heparin coat did not affect the rate of monocyte adhesion. However, heparin-coating reduced the induction of TF-PCA of non-adherent and adherent monocytes by 17 and 33% (p 0.001 and p 0.0003), respectively. Heparin-coating in the absence of monocytes, totally inhibited the clotting of recalcified plasma (p 0.003). In contrast, in the presence of adherent monocytes expressing TF-PCA, surface-bound heparin did not inhibit clotting. However, inclusion of heparin in a plasma concentration of 8.9 IU/ml totally inhibited the activation of coagulation.
It is apparent that heparin-coating of an artificial surface is an efficient means to inhibit coagulation of recalcified plasma, but much less so when procoagulant monocytes are adherent to the coated surface. The present findings are of clinical relevance, since monocytes will adhere to blood contacting surfaces of extracorporeal circuits or to implanted vascular prostheses and subsequently express TF-PCA, and this may promote thromboembolism.
-
References
- 1 van Oeveren W, Wildevuur ChRH. Blood compatibility of cardiopulmo-nary bypass circuits. Perfusion 1987; 2: 237-44.
- 2 Heyman PW, Cho CS, McRea JC, Olsen DB, Kim SW. Heparinized polyurethanes: in vitro and in vivo studies. J Biomed Mater Res 1985; 19: 419-36.
- 3 Pasche B, Kodama K, Larm O, Olsson P, Swedenborg J. Thrombin inactivation on surfaces with covalently bonded heparin. Thromb Res 1986; 44: 739-48.
- 4 Toomasian JM, Hsu LC, Hirschl RB, Heiss KS, Hultquist KA, Bartelett RH. Evaluation of Duraflo II heparin coating in prolonged extra corporeal membrane oxygenation. ASAIO Trans 1988; 34: 410-4.
- 5 von Segesser LK, Turina M. Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1989; 98: 386-96.
- 6 Palatianos GM, Dewanjee MK, Kapadvanjwala M, Novak S, Sfacianakis GN, Kaiser GA. Cardiopulmonary bypass with a surface-heparinized extra-corporeal perfusion system. ASAIO Trans 1990; 36: M476-9.
- 7 Tong SD, Rolfs MR, Hsu LC. Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits. ASAIO Trans 1990; 36: M654-6.
- 8 Videm V, Svennevig JL, Fosse E, Semb B, Østerud A, Mollnes TE. Reduced complement activation with heparin-coated oxygenator and tubing in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103: 809-13.
- 9 Gu YJ, van Oeveren W, van der Kamp KWHJ, Akkerman C, Boonstra PW, Wildenvuur ChRH. Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991; 6: 221-5.
- 10 Gu YJ, van Oeveren W, Boonstra PW, Huyzen RJ, Wildevuur ChRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917-22.
- 11 Elgue G, Blombäck M, Olsson P, Riesenfeld J. On the mechanisms of coagulation inhibition on surfaces with end point immobilised heparin. Thromb Haemost 1993; 70: 289-93.
- 12 Kappelmayer J, Bernabei A, Edmunds Jr. H, Edgington TS, Colman RW. Tissue factor is expressed during simulated extracorporeal circulation. Circ Res 1993; 72: 1075-81.
- 13 Barstad RM, Øvrum E, L-Ringdal MA, Øystese R, Hamers MJAG, Veiby OP, Rolfsen T, Stephens RW, Sakariassen KS. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haemat 1996; 94: 517-25.
- 14 Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardio-pulmonary bypass. Blood 1993; 82 (11) 3350-7.
- 15 Boisclair MD, Philippou H, Lane DA. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coag Fibrinolysis 1994; 4: 1007-21.
- 16 Barstad RM, Hamers MJAG, Kierulf P, Westvik Å-B, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIa dependent platelet-thrombus formation when exposed to flowing non-anticoagulated human blood. Atheroscler Thromb Vasc Biol 1995; 15: 11-6.
- 17 Barstad RM, Hamers MJAG, Stephens RW, Sakariassen KS. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa dependent arterial thrombus formation. Blood 1995; 86: 212-8.
- 18 van Ginkel GCW, van Aken WG, Oh JIH, Vreeken J. Stimulation of monocyte procoagulant activity by adherence to different surfaces. Br J Haematol 1977; 37: 35-45.
- 19 Kalman PG, Rotstein OD, Niven J, Glyn MFX, Romaschin AD. Differential stimulation of macrophage procoagulant activity by vascular grafts. J Vasc Surg 1993; 3: 531-7.
- 20 Fan ST, Edgington TS. Coupling of the adhesive receptor CD11b/CD18 to functional enhancement of effector macrophage tissue factor response. J Clin Invest 1991; 87: 50-7.
- 21 Fan ST, Edgington TS. Integrin regulation of leukocyte inflamatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 1993; 150: 2972-80.
- 20 Bøyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976; 5: 9-15.
- 21 Larm O, Larsson R, Olsson P. A non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Dev Art Org 1983; 11: 161-3.
- 22 Brandtzæg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-207.
- 23 Altieri DC. Coagulation assembly on leukocytes in transmembrane signalling and cell adhesion. Blood 1993; 81: 569-79.
- 24 Øvrum E, Holen EÅ, Tangen G, Brosstad F, Abdelnoor ML, Ringdal M-A, Øystese R, Istad R. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995; 60: 365-71.
- 25 Rao LV, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-7.